Abstract
Cytochrome P450 (P450) reaction phenotyping is a key process toward accurately determining the contribution of different P450s to the metabolism of new chemical entities. The significance of P450s to drug disposition has led to the identification of selective chemical and antibody inhibitors for individual P450 enzymes. Despite these advances, the maximal inhibition attainable is limited by the use of inhibitor concentrations that maintain selectivity for the individual P450s. Thus, most commercially available inhibitors produce a maximal inhibition of approximately 80%. Herein, the combination of chemical plus antibody inhibitors is explored to find whether P450 3A could be selectively and completely (>99%) inhibited by using both inhibitors simultaneously.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
Area Under Curve
-
Cytochrome P-450 CYP3A / immunology
-
Cytochrome P-450 CYP3A / metabolism
-
Cytochrome P-450 CYP3A Inhibitors*
-
Cytochrome P-450 Enzyme Inhibitors
-
Cytochrome P-450 Enzyme System / metabolism
-
Drug Interactions
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Hydroxytestosterones / metabolism
-
Ketoconazole / pharmacology
-
Microsomes, Liver / drug effects
-
Microsomes, Liver / enzymology*
-
Midazolam / analogs & derivatives
-
Midazolam / metabolism
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / metabolism
-
Testosterone / analogs & derivatives
-
Testosterone / metabolism
Substances
-
Antibodies, Monoclonal
-
Cytochrome P-450 CYP3A Inhibitors
-
Cytochrome P-450 Enzyme Inhibitors
-
Enzyme Inhibitors
-
Hydroxytestosterones
-
Protein Isoforms
-
Testosterone
-
6 beta-hydroxytestosterone
-
Cytochrome P-450 Enzyme System
-
1-hydroxymethylmidazolam
-
Cytochrome P-450 CYP3A
-
Midazolam
-
Ketoconazole